Dosage & Administration Efficacy safety testing Drug label Prior authorization Financial assistance

Pomalyst

(pomalidomide)

pomalidomide 1 MG Oral Capsule [Pomalyst]pomalidomide 2 MG Oral Capsule [Pomalyst]

View 2 more

Dosage & administration

* MM: 4 mg per day taken orally on Days 1 through 21 of repeated 28-day cycles until disease progression . Refer to section 14.1 for dexamethasone dosing
* KS: 5 mg per day taken orally on Days 1 through 21 of repeated 28-day cycles until disease progression or unacceptable toxicity .
* Modify the dosage for certain patients with renal impairment or hepatic impairment

eficacy, safety & testing

Pomalyst clinical details

Mechanism of Action (MOA)

Clinical Trial: Multiple Myeloma - Pomalyst Doublet Pd

Efficacy: Multiple Myeloma - Pomalyst Doublet Pd

Safety Profile: Multiple Myeloma - Pomalyst Doublet Pd

Dosing: Multiple Myeloma - Pomalyst Doublet Pd

Renal Dosing: Multiple Myeloma - Pomalyst Doublet Pd

Dose Modifications: Multiple Myeloma - Pomalyst Doublet Pd

Clinical Trials: Multiple Myeloma - Pomalyst Triplet DPd

Efficacy: Multiple Myeloma - Pomalyst Triplet DPd

Safety Profile: Multiple Myeloma - Pomalyst Triplet DPd

Trial Data: Multiple Myeloma - Pomalyst Triplet Pd+Dara SC

Trial Data: Multiple Myeloma - Pomalyst Triplet DPd (MM-014)

REMS

REMS Sign-In Portal

Dosing: Kaposi Sarcoma

Pomlayst REMS

drug label

Pomalyst prescribing information

Have more Pomalyst questions?

Submit MSL Request

Learn More

Need to report a Pomalyst issue?

ONLINE FORMReport adverse event

Learn More

prior authorization

Pomalyst Prior authorization resources

Complete Letter of Medical Necessity

NOT PROVIDED BY BRANDCoverage Authorization Request

Coverage Authorization Appeals

Commercial Claim Denial Appeal/Redetermination Letter

Medically Unlikely Edit (MUE) Appeal Letter

Learn More

Benefits investigation

Pomalyst Enrollment Form

Pomalyst Enrollment Form - Spanish

Learn More

Reimbursement help (FRM)

Receive Assistance from an FRM Regarding Reimbursement Information

Learn More

financial assistance

Pomalyst Financial assistance options

Co-pay savings program

commercial only

Pomalyst Enrollment Form

Pomalyst Enrollment Form - Spanish

Enroll in Patient Savings Program

Learn More

Overview

Reduce patient OOP costs for drug (and occasionally for drug administration/infusion costs or drug-related test costs)

Patient benefit

A portion (or all) of patient OOP (deductible, copay), typically up to monthly and/or annual max

Patient eligibility

Patient must enroll or activate (may permit HCPs to enroll on patient’s behalf for HCP-administered drugs)
Generally, must have commercial insurance (rarely, may permit uninsured patients to use)
May never be used with government insurance

How to sign up

Cards may be downloadable digital cards or hard copies
Some pharmacos offer debit cards with pre-loaded copay benefit
Typically, available through multiple channels (e.g., rep to HCP to patient; pharmacy to patient; patient via website, Hub live agent, or copay vendor (live agent or IVR); patient and HCP via Hub enrollment form)
Some HCP-administered product programs permit HCPs to enroll on a patient’s behalf through via Hub form

Bridge program

commercial only

Learn More

Overview

Provide patient immediate access to therapy during an insurance delay (typically new starts; some may cover change in insurance)
Limited time/ fill (typically 7-30 days; some may offer additional fill for continued delay up to certain limit)

Patient benefit

100% free (outside of insurance)

Patient eligibility

HCP must enroll patient
May be limited to commercially insured patients (i.e., no government beneficiaries); some programs may allow government beneficiaries

How to sign up

Typically HCP assisted enrollment (via form)

Foundation programs

under insured

no insurance

goverment insurance

65+

Pomalyst Enrollment Form

Pomalyst Enrollment Form - Spanish

Learn More

Overview

Charitable 501(c)(3) organizations provide direct cost-sharing and other support (e.g., travel, counseling) through disease-state funds to indigent patients on first-come first-served basis
These organizations may receive financial contributions from drug manaufacturers for particular disease-state funds that cannot provide funds directly to patients - the foundation must be independent/unaligned

Patient benefit

Patients apply for grants that cover a portion (or all) of their out-of-pocket costs (deductibles and co-pays) until the grant is exhausted

Patient eligibility

Patients must apply and meet eligibility criteria including income level (typically a multiple of federal poverty line), specific diagnosis, insurance status, etc.

How to sign up

Patients submit proof of out-of-pocket drug costs to charities for reimbursement

patient education

Pomalyst Patient education

Getting started on Pomalyst

NOT PROVIDED BY BRANDInstructions For Use: Multiple Myeloma

NOT PROVIDED BY BRANDInstructions For Use: Kaposi Sarcoma